

February 24, 2017
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**Notice concerning the Appointment of the Representative Director
and Nominations for the Board of Directors/ Auditor Candidates**

SymBio Pharmaceuticals Limited (“the Company”) announces that at a Board of Directors’ Meeting held today, it has been decided to formally propose the approval of the appointment of a new Representative Director of the Company at the 12th Ordinary General Meeting of Shareholders to be held on March 29, 2017, (the “Shareholders Meeting”) and at the Board of Directors’ Meeting (the “Directors Meeting”) to be held immediately following the Shareholders Meeting.

The Company shall also submit a proposal to the Shareholders Meeting on the election of the Company’s Directors and Auditors as follows.

1. Nomination of Candidates for Representative Director (Newly nominated)

(1) Reason for Nomination

In order to further strengthen the Company’s management organization, aiming to increase its corporate value.

(2) Name and New Title

Mr. Kazuo Asakawa, Representative Director, Executive Vice President, COO and Head of the Company’s Japan Business Unit

(3) Date of Assumption of Office

March 29, 2017

(4) Profile of the Candidate

Date of Birth	Career Summary		Number of Company Shares Owned
February 25, 1954	April 1979	Joined Sandoz Japan K.K.	None
	December 1994	General Manager, Central Nervous System Unit, Nippon Roche K.K.	
	June 1996	Group Manager, Special Products Group, Sandoz Japan K.K.	
	April 1997	General Manager, Marketing Department, Novartis Pharma K.K.	

	April 2002	Corporate Officer, Head of Transplantation & Immunology Business Division, Novartis Pharma K.K.	
	December 2005	Executive Director, Head of Oncology Business Unit, Novartis Pharma K.K.	
	December 2015	Joined the Company Head of the Company's Japan Business Unit	
	March 2016	Corporate Officer, Executive Vice President, COO, and Head of the Company's Japan Business Unit (current positions)	
	(Significant concurrent position) Not applicable		

* Mr. Kazuo Asakawa is expected to be appointed as a member of the Company's Board of Directors at the Shareholders Meeting.

2. Nomination of Candidates as Members of the Board of Directors and as Auditors (As of March 29, 2017)

(1) Nomination of Candidates as Members of the Board of Directors (Re-nomination)

Mr. Fuminori Yoshida, Representative Director, President & CEO

Ms. Naoko Iino, Outside Director

Dr. George Morstyn, Outside Director

Dr. Milton Grannatt, Outside Director

(2) Nomination of Candidates as Members of the Board of Directors (Newly nominated)

Mr. Kazuo Asakawa

* Mr. Kazuo Asakawa is expected to be newly appointed as the Company's Representative Director and Executive Vice President at the Directors Meeting after being newly appointed as a member of the Company's Board of Directors at the Shareholders Meeting. For Mr. Asakawa's profile, please refer to "1. Nomination of Candidates for Representative Director (Newly nominated)"

(3) Nomination of Candidates as Members of the Board of Directors (Outside Directors) (Newly nominated)

Mr. Sumio Ariyoshi

Profile of the Candidate

Date of Birth	October 11, 1951	
Career Summary	April 1974	Joined Mitsubishi Corporation
	June 1992	President & CEO, MC Medical, Inc.
	April 2006	Senior Vice President, Division COO, Human Care Business Div., Mitsubishi Corporation
	April 2011	Representative Director and President, MC Healthcare, Inc.
	October 2016	Advisor, SHINRYO CO., LTD. (current)

(4) Nomination of Candidates for Outside Auditors (Newly nominated)

Mr. Kiyoshi Watanabe (Full-time)

Profile of the Candidate

Date of Birth	May 16, 1951	
Career Summary	April 1974	Joined The Industrial Bank of Japan, Limited (currently Mizuho Bank, Ltd.)
	June 1998	Chief of The Americas Corporate Credit Office, Credit Department, The Industrial Bank of Japan, Limited (resided in New York)
	June 2003	General Manager, Corporate Planning Office, Kyowa Hakko Kogyo Co., Ltd.
	April 2005	General Manager, Medicine Planning Department, Kyowa Hakko Kogyo Co., Ltd.
	October 2008	General Manager, Planning and Administration Department, KYOWA HAKKO BIO CO., LTD.
	February 2011	Full-time Audit & Supervisory Board Member, Kawaguchi Chemical Industry Co., Ltd.
	June 2015	Member of the Audit & Supervisory Board, Toho Acetylene Co., Ltd. (current)

Mr. Shigetoshi Matsumoto

Profile of the Candidate

Date of Birth	August 12, 1949	
Career Summary	April 1972	Joined CHUGAI PHARMACEUTICAL CO., LTD.
	April 2002	General Manager of the Audit Office, CHUGAI PHARMACEUTICAL CO., LTD.
	March 2007	Full-time Audit & Supervisory Board Member, CHUGAI PHARMACEUTICAL CO., LTD.
	April 2011	Senior Advisor, CHUGAI PHARMACEUTICAL CO., LTD.
	October 2011	Advisor, APO PLUS STATION Co., Ltd.
	June 2015	Senior Advisor, Protiviti LLC
	October 2015	Audit Practice Counselor, Japan Audit & Supervisory Board Members Association (current)

3. Members of the Board of Directors and the Auditors who shall resign

(1) Board of Directors

Mr. Lowell Sears, Outside Director

Mr. George Vandeman, Outside Director

(2) Auditors

Mr. Takeshi Masuda, Outside Auditor (Full-time)

Mr. Chikara Shimazaki, Outside Auditor

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125